MEMBER SIGN IN
eLEARNING SIGN IN
BECOME A MEMBER

Key Opinion Leader (KOL):
What Is a KOL & What Do They Do?

In healthcare and the pharmaceutical industry, certain experts have influence that extends beyond their own institution, practice, or research group. These experts are commonly referred to as Key Opinion Leaders (KOLs). They play an important role in how new treatments are studied, discussed, evaluated, and adopted in clinical practice.

For Medical Science Liaisons (MSLs), KOLs are among the most important external stakeholders to understand and engage. Their scientific expertise, clinical experience, and peer recognition can help Medical Affairs teams identify unmet needs, interpret emerging evidence, and support meaningful scientific exchange.

In this article, you’ll learn what a Key Opinion Leader (KOL) is, what KOLs do, why they play a critical role in pharma and healthcare, and how Medical Affairs teams identify, engage, and collaborate with them through practical examples and illustrative scenarios.

What Is a Key Opinion Leader (KOL)?

A Key Opinion Leader (KOL) is a highly respected expert—often a physician, researcher, scientist, academic leader, or specialist clinician—who influences clinical decisions, research priorities, and industry strategy through deep expertise in a specific therapeutic area.

In pharma, KOLs may advise on clinical trial design, interpret scientific data, educate healthcare professionals, contribute to treatment guidelines, or provide input to regulatory, access, or policy-related discussions, helping ensure new treatments meet real-world medical needs.

The following graphic shows popular alternative titles for Key Opinion Leader (KOL) based on a global survey conducted by the MSL Society. The most commonly used alternative terms were “External Expert,” “Thought Leader (TL),” and “Medical Expert.”

Most commonly used terms for Key Opinion Leaders globally.
Most commonly used terms for Key Opinion Leaders globally.

Source: 2017 Global “KOL” Term Survey

What Do Key Opinion Leaders (KOLs) Do?

Because KOLs work across different settings, their day-to-day responsibilities vary. However, in the context of Medical Affairs and pharmaceutical collaboration, their role consistently centers on providing scientific expertise and helping shape how new therapies are developed, evaluated, and adopted. KOLs commonly support activities such as:

Clinical trial design and data interpretation:

KOLs advise on study design, endpoint selection, and data interpretation to help ensure research is scientifically sound and clinically relevant.

Healthcare professional education:

KOLs educate healthcare professionals on emerging therapies, disease-state insights, and evolving evidence.

Treatment guidelines and publications:

KOLs contribute to guidelines, consensus statements, and peer-reviewed publications that may shape standards of care.

Regulatory and access considerations:

KOLs provide expert perspectives on unmet needs, benefit-risk profiles, and real-world applicability.

Medical congresses and educational events:

KOLs speak at congresses, advisory boards, webinars, and educational programs where they share new data and expert perspectives.

Research activity and professional engagement:

KOLs maintain scientific credibility by publishing research, participating in studies, and engaging through scientific or digital channels.
For Medical Science Liaisons (MSLs), understanding what a KOL does helps assess their influence, determine the right engagement strategy, and tailor scientific discussions that align with the KOL’s expertise and impact.

Why Are KOLs Important in Pharma & Biotech?

Key Opinion Leaders (KOLs) are important because they help connect scientific innovation with real-world clinical practice. Their expertise can inform how new treatments are studied, evaluated, communicated, and adopted across healthcare settings.

KOLs are important because they:

Bridge research
and real-world care
KOLs help companies understand what matters to clinicians, researchers, healthcare systems, and patients in everyday practice.
Inform Medical
Affairs strategy
KOL insights can shape evidence generation plans, trial priorities, scientific communication, and educational needs.
Strengthen
scientific credibility
KOLs provide independent clinical and scientific perspectives that help ensure discussions remain grounded in evidence and real-world medical needs.
Identify unmet needs
and evidence gaps
KOLs can highlight clinical challenges, patient care barriers, and unanswered scientific questions that may not be fully visible from internal data alone.
Support launch readiness
and adoption planning
KOL perspectives can help Medical Affairs and MSL teams anticipate questions, barriers, and educational needs before and after a new therapy becomes available.

How Medical Affairs Teams Work With KOLs

Working with Key Opinion Leaders (KOLs) is a core responsibility of Medical Affairs teams, particularly Medical Science Liaisons (MSLs). Effective KOL collaboration is built on credible scientific exchange, clear objectives, and a strong understanding of each expert’s therapeutic area, influence, and interests.

MSL Society research reinforces the importance of this scientific focus. In a survey of 203 KOLs across 33 specialties, 76% reported that scientific or medical discussions with MSLs are more valuable or much more valuable than conversations with sales representatives.

MSLS survey showing KOLs value scientific discussions with MSLs more than sales rep discussions.
MSLS survey showing KOLs value scientific discussions with MSLs more than sales rep discussions.

Source: 2021 Key Opinion Leaders Reveal the Value of Medical Science Liaisons Survey

At a high level, Medical Affairs teams work with KOLs through three connected activities: identification, engagement, and measurement.

Identifying the Right KOLs

KOL identification involves finding experts whose knowledge, influence, and professional activity align with a therapeutic area or Medical Affairs strategy. Teams may assess publication history, clinical trial involvement, guideline participation, conference activity, academic leadership, peer recognition, and digital visibility.

The goal is not only to identify the most visible experts, but to understand which KOLs are most relevant to a specific scientific question, product lifecycle stage, patient population, or evidence need.

Engaging Through Scientific Exchange

Once relevant KOLs are identified, Medical Affairs teams engage them through credible, non-promotional scientific exchange. This may include one-to-one MSL discussions, advisory boards, medical congress meetings, clinical trial collaboration, disease-state education, or virtual and hybrid engagement.

Effective engagement should be relevant, consistent, and compliant. Each interaction should provide scientific value, respect the KOL’s expertise, and follow applicable regulations, fair market value requirements, and internal policies.

Measuring Engagement and Insights

Measuring KOL engagement helps Medical Affairs teams understand whether their interactions are meaningful and aligned with strategy. Rather than focusing only on the number of meetings, teams may evaluate insight quality, scientific relevance, responsiveness, contribution to evidence generation, and alignment with Medical Affairs objectives.

Strong measurement helps teams refine engagement plans, identify unmet needs, and support KOL collaboration that creates meaningful scientific and clinical value.

Build Your KOL
Engagement Skills

Effective KOL engagement requires more than knowing who the right experts are. MSLs also need strong scientific communication, clear engagement strategy, and the ability to navigate challenging expert conversations.

Explore MSL Society training and resources to strengthen your KOL engagement skills and continue building your Medical Affairs expertise.

Examples Of KOL Collaboration In Practice

KOL collaboration can look different depending on the therapeutic area, product lifecycle stage, and Medical Affairs priorities. The following illustrative scenarios show how KOLs may support scientific discussion, evidence planning, and Medical Affairs strategy in practice.

ONCOLOGY:
Shaping Clinical Trial Design

An oncology KOL is invited to provide scientific input on a proposed Phase III study for an investigational therapy. Based on their clinical experience, they highlight considerations around endpoint selection, patient stratification, and how the study design reflects real-world treatment patterns. Medical Affairs and clinical development teams can use this feedback to better understand whether the proposed study is clinically relevant and feasible.

RARE DISEASE:
Refining Evidence Generation Plans

In a rare metabolic disorder, a KOL with deep disease-state expertise participates in an advisory board. During the discussion, they identify gaps in natural history data, patient-reported outcomes, and long-term follow-up needs. These insights help Medical Affairs better understand what evidence may be needed to support clinicians, patients, and future scientific exchange.

CARDIOVASCULAR MEDICINE:
Supporting Launch Readiness

Before a new therapy becomes available, a cardiovascular KOL shares insights into current treatment pathways, common clinical questions, and potential barriers to adoption. This helps the MSL team prepare for future scientific discussions, refine educational priorities, and anticipate the types of evidence healthcare professionals may want to review.
These examples show how KOLs can provide scientific credibility, clinical perspective, and practical insight across the lifecycle of a therapy.

Frequently Asked Questions

What does KOL stand for?

KOL stands for Key Opinion Leader. In healthcare and pharma, a KOL is a respected medical, scientific, or clinical expert whose knowledge and influence help shape how others understand a disease area, treatment approach, or emerging therapy.

Are KOLs influencers?

Not in the traditional sense. While both KOLs and influencers can shape opinions, KOLs are defined by their scientific expertise, clinical experience, research activity, and professional credibility—not by audience size or popularity. Some KOLs may have a strong digital presence, but expertise is what qualifies them as KOLs.

What is the difference between a KOL and a DOL?

A Key Opinion Leader (KOL) is a medical or scientific expert whose influence usually comes from research, publications, clinical leadership, guideline involvement, or peer recognition. A Digital Opinion Leader (DOL) builds influence primarily through digital platforms such as LinkedIn, X (formerly Twitter), YouTube, blogs, or online professional communities.

Some experts can be both KOLs and DOLs. The main difference is that KOL influence is usually rooted in scientific or clinical authority, while DOL influence is more visible through online education, digital reach, and real-time professional discussion.

What is a Tier 1 KOL?

A Tier 1 KOL is a high-impact expert whose influence often extends nationally or globally. Tier 1 KOLs may include guideline authors, major clinical trial investigators, specialty society leaders, highly cited researchers, or experts who shape scientific consensus in a therapeutic area.

Because of their reach and strategic importance, Tier 1 KOLs are often among the highest-priority external experts for Medical Affairs teams.

Are all KOLs doctors?

No. While many KOLs are physicians, others may be PhD scientists, pharmacists, nurse specialists, academic researchers, or other healthcare experts. The defining factor is not a specific credential, but relevant expertise, credibility, and influence within a therapeutic area.

Are KOLs paid?

KOLs may be compensated for specific activities such as advisory boards, consulting, speaking engagements, or medical education, where permitted and depending on the activity and applicable regulations. These arrangements should follow compliance requirements, fair market value principles, transparency rules, and internal company policies.

References

  1. Medical Science Liaison Society. (2017). Global “KOL” Term Survey.
  2. Medical Science Liaison Society. (2021). Key Opinion Leaders Reveal the Value of Medical Science Liaisons Survey.